Skip to main content

JAKi CV Safety in Younger Adults

Dr. David Liew | ACR 2026

Transcription

David Lou here as part of RheumNow's rheumatoid arthritis coverage from ACR Convergence 2026. I wanted to point out a poster on the poster floor which looks at TriNetX data, and immediately when people say that nowadays everyone gets a bit cautious, but I think this has been done quite well and it really addresses a point that has sometimes been missing from the discussion.

What is that? Well, it's about JAK inhibitor safety in younger adults. One of the real victims of any loss of nuance around oral surveillance has been what happens to younger adults who might benefit from JAK inhibitors, and the discussions, the nuances of discussions around starting a JAK inhibitor. And you worry that people might not be getting the best therapies that they could be, because these conversations are difficult to navigate from many different directions.

So this is exactly what this analysis looks at. It looks at these big data but looks at younger adults 18 to 64 with rheumatoid arthritis starting therapy, compares JAK inhibitors to TNF inhibitors, looks at cardiovascular outcomes — some new major adverse cardiovascular events, arterial cardiovascular events, VTEs — and tries to see whether there's any signal there, knowing that we haven't always seen the oral surveillance replicated in observational data. But what's very clear here is that there is no signal in younger adults as far as this is concerned.

So I think, what do we take away from that? And look, there's some nuances with the data that I'm not going to drag you through, but just to say that I think as much of the discussion has been, there's been debate within the enriched at-risk population that oral surveillance targeted in terms of JAK inhibitor safety, and that's been well documented. Outside of that, and realistically when you break down oral surveillance outside of the patients who have actually had outright cardiovascular events in the past, you have to say that the risk is very close to what you see with TNF inhibitors.

And we've got to be very cautious about not disadvantaging those types of patients away from effective therapies, knowing that we should keep the nuance, keep the balance, and be aware of what the regulatory warning does show.

So for lots more on rheumatoid arthritis, you know where to go — RheumNow.com.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×